Sugi Predict

Sugi Predict / Compounds / SCHEMBL19207835

SCHEMBL19207835

SCHEMBL19207835

CCOC(=O)c1cc(C#N)[nH]n1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ POLB P06746 1/20 0.46
▸ THRB P10828 2/20 0.45
▸ TP53 P04637 2/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ GLA P06280 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ MAPT P10636 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ APOBEC3G Q9HC16 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ PDE4D Q08499 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5355374 0.82 MAPK1 (0.59) KMT2AL3MBTL1POLBCYP1A2KDM4E
SCHEMBL1665229 0.78 DAO (0.58) KMT2ANPSR1L3MBTL1POLBTHRB
SCHEMBL24117299 0.78 MAPK1 (0.39) KMT2AL3MBTL1POLBTP53KDM4E
SCHEMBL1007015 0.77 MAPK1 (0.61) KMT2ANPSR1L3MBTL1POLBTHRB
SCHEMBL163302 0.77 KMT2A (0.54) KMT2ANPSR1L3MBTL1POLBTHRB
SCHEMBL1423671 0.77 KMT2A (0.54) KMT2ANPSR1L3MBTL1POLBTHRB
SCHEMBL24758142 0.76 HCAR2 (0.37) KDM4E
SCHEMBL13369577 0.76 NPSR1 (0.52) KMT2ANPSR1L3MBTL1POLBTHRB
Ethane SCHEMBL6614658 0.76 MAPK1 (0.59) KMT2ANPSR1L3MBTL1POLBTHRB
SCHEMBL17593217 0.76 KMT2A (0.52) KMT2ANPSR1L3MBTL1POLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 — — US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 — — US disclosed
US-20240150376-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2024-05-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
CN-114437105-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-05-06 — — CN disclosed
CN-109071504-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-03-08 — — CN disclosed
US-20200317691-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2020-10-08 — — US disclosed
US-20200317691-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2020-10-08 — — US disclosed
US-10604535-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2020-03-31 — — US disclosed
US-9896458-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2018-02-20 — — US disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 — — US disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 KMT2A 1868/4885NPSR1 2688/4885L3MBTL1 3455/4885
US-20200317691-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB KMT2A 1816/4885NPSR1 4297/4885L3MBTL1 2905/4885
US-20240150376-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB KMT2A 1816/4885NPSR1 4297/4885L3MBTL1 2905/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB KMT2A 1816/4885NPSR1 4297/4885L3MBTL1 2905/4885
US-20230043400-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB KMT2A 1816/4885NPSR1 4297/4885L3MBTL1 2905/4885
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB KMT2A 1816/4885NPSR1 4297/4885L3MBTL1 2905/4885
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB KMT2A 1816/4885NPSR1 4297/4885L3MBTL1 2905/4885
US-10604535-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB KMT2A 1816/4885NPSR1 4297/4885L3MBTL1 2905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.